Description
Entrectinib Uses
Entrectinib is a kinase inhibitor used for the Treatment of:
- ROS1-Positive Non-Small Cell Lung Cancer
- NTRK Gene Fusion-Positive Solid Tumors
Dosage: The recommended entrectinib Capsule dose for patients with ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors is 600 mg orally once daily with or without food until the disease is progressive or unacceptable toxicity is noticed. Swallow the entrectinib capsules whole. Do not open, crush, chew, or dissolve the contents of the capsule. In case of missed dose, patients are instructed to make up that dose unless the next dose is due within 12 hours. If vomiting occurs promptly after taking a dose, patients are instructed to repeat that dose.
Side Effects: The most commonly reported entrectinib Capsule side effects include:
- Fatigue
- Constipation
- Dysgeusia
- Edema
- Dizziness
- Diarrhea
- Nausea
- Dysesthesia
- Dyspnea
- Myalgia
- Cognitive impairment
- Increased weight
- Cough
- Vomiting
- Pyrexia
- Arthralgia
- Vision disorders
Storage: Store Rozlytrek (Entrectinib) at room temperature (15-30°C). This medicine should not be used following the expiry date shown on the pack.
Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the ROZLYTREK at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the ROZLYTREK Capsules.
Buying Procedure: In order to buy ROZLYTREK, you can contact us at our Toll-free number 1800 889 1064 or on WhatsApp number +919310090915 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports.
Conclusion: In conclusion, therapy with entrectinib capsules expands the range of treatment options for advanced NTRK +Ve solid tumours and ROS1 +Ve NSCLC, and may be of particular value in patients with existing CNS metastases and those who are at risk of developing CNS metastases.